TIOPRONIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for tiopronin and what is the scope of patent protection?
Tiopronin
is the generic ingredient in five branded drugs marketed by Mission Pharmacal, Amneal, Ph Health, Teva Pharms Inc, Torrent, Mission Pharma, Casper Pharma Llc, and Teva Pharms Usa Inc, and is included in nine NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.Eight suppliers are listed for this compound.
Summary for TIOPRONIN
| US Patents: | 1 |
| Tradenames: | 5 |
| Applicants: | 8 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 97 |
| Clinical Trials: | 5 |
| Patent Applications: | 4,492 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TIOPRONIN |
| What excipients (inactive ingredients) are in TIOPRONIN? | TIOPRONIN excipients list |
| DailyMed Link: | TIOPRONIN at DailyMed |
Recent Clinical Trials for TIOPRONIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| NYU Langone Health | Phase 2 |
| New York University School of Medicine | Phase 2 |
| Revive Therapeutics, Ltd. | Phase 2 |
Pharmacology for TIOPRONIN
| Drug Class | Reducing and Complexing Thiol |
| Mechanism of Action | Cystine Disulfide Reduction |
Anatomical Therapeutic Chemical (ATC) Classes for TIOPRONIN
US Patents and Regulatory Information for TIOPRONIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | TIOPRONIN | tiopronin | TABLET, DELAYED RELEASE;ORAL | 216456-002 | Jul 22, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Ph Health | TIOPRONIN | tiopronin | TABLET, DELAYED RELEASE;ORAL | 217219-002 | Feb 24, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Casper Pharma Llc | TIOCYSTIN | tiopronin | TABLET;ORAL | 212927-001 | Jun 2, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mission Pharmacal | THIOLA EC | tiopronin | TABLET, DELAYED RELEASE;ORAL | 211843-001 | Jun 28, 2019 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch